Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Aug 17, 2026
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
News Related to CDK2
Related coverage linked through entity extraction aliases.
AI platform models protein flexibility to accelerate drug design
Apr 15, 2026
Researchers developed an AI-driven drug discovery platform that models protein flexibility during molecular binding. The suite includes YuelDesign, YuelPocket and YuelBond.
CDK Inhibitor Landscape: From Approved CDK4/6 Drugs to Next-Generation CDK2 Strategies
Apr 19, 2025
CDK4/6 inhibitors have transformed HR+/HER2− breast cancer treatment, while emerging resistance mechanisms are driving development of selective CDK2 inhibitors and dual CDK2/4 strategies to address treatment failure.